BibTex format
@article{de:2024:10.1515/nipt-2023-0025,
author = {de, Mendoza C and Taylor, G and Gessain, A and Thoma-Kress, AK and Bangham, C and Vesterbacka, J and Accolla, R and Bazarbachi, A and van, Weyenbergh J and Cook, L and Casseb, J and Ramos, JC and Rosadas, C and Macchi, B and Cassar, O and Soriano, V},
doi = {10.1515/nipt-2023-0025},
journal = {NeuroImmune Pharmacology and Therapeutics},
pages = {61--69},
title = {Virology, pathogenesis, epidemiology and clinical management of HTLV-1 infection. Proceedings of the 30th HTLV European research network (HERN 2023)},
url = {http://dx.doi.org/10.1515/nipt-2023-0025},
volume = {3},
year = {2024}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - The 30th workshop of the HTLV European Research Network (HERN) was held in Madrid on September 15–16, 2023. Over fifty researchers from Europe and America convened for a two-day conference to update and discuss basic science, epidemiology, clinical management and therapeutics for patients with HTLV-1 infection. Scientific topics addressed included new estimates for HTLV-1 in Europe; impact of antenatal screening on mother-to-child HTLV-1 infections; new insights into the molecular epidemiology of HTLV-1; reports of elite controllers for HTLV-1 infection; role of antiretrovirals as HTLV-1 pre-exposure prophylaxis; and prospects for a HTLV-1 vaccine. The group agreed to submit a formal request to WHO for increasing the global surveillance and awareness of HTLV-1. This viral infection is a potentially life-threatening, neglected condition with neither treatment nor vaccine. At this time, expanding HTLV-1 screening is the most effective way to reduce viral dissemination.
AU - de,Mendoza C
AU - Taylor,G
AU - Gessain,A
AU - Thoma-Kress,AK
AU - Bangham,C
AU - Vesterbacka,J
AU - Accolla,R
AU - Bazarbachi,A
AU - van,Weyenbergh J
AU - Cook,L
AU - Casseb,J
AU - Ramos,JC
AU - Rosadas,C
AU - Macchi,B
AU - Cassar,O
AU - Soriano,V
DO - 10.1515/nipt-2023-0025
EP - 69
PY - 2024///
SN - 2750-6665
SP - 61
TI - Virology, pathogenesis, epidemiology and clinical management of HTLV-1 infection. Proceedings of the 30th HTLV European research network (HERN 2023)
T2 - NeuroImmune Pharmacology and Therapeutics
UR - http://dx.doi.org/10.1515/nipt-2023-0025
VL - 3
ER -